Positive safety result supports advance to clinical trials
Filed with ASX · · 2 pages · English
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- New data demonstrates EmtinB activity in autoimmune diseases
- NSB 1HY22 Key Activity Highlights
- Successful completion of key studies in lead up to Phase I
- Positive off-target safety assessment of EmtinB
- Positive results in biomarker characterisation of Emtins
Later from Neuroscientific Biopharmaceuticals
- HREC Submission for early-phase Clinical Trial
- Ethics Approval Granted for Early-Phase Clinical Trial
- Positive results in MS animal study
- First Subject Recruited for Early-Phase Clinical Trial
- HREC Submission for Phase I Clinical Trial
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals